{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:58:21Z","timestamp":1774522701142,"version":"3.50.1"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The use of hypofractionated radiotherapy (HFRT) after prostatectomy has expanded because of its radiobiological advantages and its potential to reduce treatment burden. Stereotactic body radiotherapy (SBRT), an even more condensed treatment approach, has recently emerged as a possible salvage option for men with biochemical recurrence, although its role remains investigational. To summarize current evidence, we performed a narrative review of published and ongoing studies evaluating moderate HFRT and SBRT for prostate bed salvage radiotherapy, drawing from MEDLINE, Embase, Cochrane CENTRAL, and ClinicalTrials.gov through May 2025. Across the available literature, moderate HFRT using 2.5\u20133.0\u00a0Gy per fraction over 15\u201328 fractions has shown favorable tumor control with generally acceptable safety, though some studies report increased late genitourinary toxicity with higher per-fraction doses or wide treatment margins. The phase III NRG-GU003 trial demonstrated non-inferiority of HFRT compared with conventional radiotherapy using patient-reported outcomes, supporting its clinical validity. Early SBRT experiences, often using 30\u201334\u00a0Gy in five fractions, have shown grade\u2009\u2265\u20092 genitourinary toxicity in up to approximately 29% of patients, while gastrointestinal toxicity has typically remained low. However, follow-up is short, and long-term safety remains uncertain. Although conventionally fractionated salvage radiotherapy remains the standard of care, current evidence supports moderate HFRT as an accepted alternative to conventional fractionation, whereas postoperative SBRT may be feasible in selected patients. Given limited long-term safety data and the potential for late toxicities to emerge many years after treatment, SBRT should remain investigational until results from ongoing trials become available.<\/jats:p>","DOI":"10.1093\/jrr\/rrag006","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:46:07Z","timestamp":1768999567000},"page":"161-169","source":"Crossref","is-referenced-by-count":0,"title":["Salvage stereotactic body radiotherapy for post-prostatectomy recurrence: are we almost there?"],"prefix":"10.1093","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6937-8042","authenticated-orcid":false,"given":"Zhe","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Therapeutic Radiology, University of Yamanashi , 1110 Shimokato, Chuo City, Yamanashi Prefecture 409-3898 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Van Ton","family":"Tran","sequence":"additional","affiliation":[{"name":"Radiotherapy Department, Oncology Center, Military Hospital 103, Vietnam Military Medical University , 261 Phung Hung Street, Ha Dong District, Ha Noi 12108 ,","place":["Vietnam"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Radiology, University of Yamanashi , 1110 Shimokato, Chuo City, Yamanashi Prefecture 409-3898 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Akita","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Radiology, University of Yamanashi , 1110 Shimokato, Chuo City, Yamanashi Prefecture 409-3898 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kan","family":"Marino","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Radiology, University of Yamanashi , 1110 Shimokato, Chuo City, Yamanashi Prefecture 409-3898 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Komiyama","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Radiology, University of Yamanashi , 1110 Shimokato, Chuo City, Yamanashi Prefecture 409-3898 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3512-1166","authenticated-orcid":false,"given":"Hiroshi","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Radiology, University of Yamanashi , 1110 Shimokato, Chuo City, Yamanashi Prefecture 409-3898 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"2026032605555587500_ref1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026032605555587500_ref2","volume-title":"EAU Guidelines","year":"2025"},{"key":"2026032605555587500_ref3","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1097\/JU.0000000000001578","article-title":"Therapies for clinically localized prostate cancer: a comparative effectiveness review","volume":"205","author":"Wilt","year":"2021","journal-title":"J Urol"},{"key":"2026032605555587500_ref4","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0022-5347(05)66452-X","article-title":"Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?","volume":"165","author":"Amling","year":"2001","journal-title":"J Urol"},{"key":"2026032605555587500_ref5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"key":"2026032605555587500_ref6","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","article-title":"Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy","volume":"25","author":"Stephenson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026032605555587500_ref7","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","article-title":"Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy","volume":"299","author":"Trock","year":"2008","journal-title":"JAMA"},{"key":"2026032605555587500_ref8","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(05)67101-2","article-title":"Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)","volume":"366","author":"Bolla","year":"2005","journal-title":"Lancet"},{"key":"2026032605555587500_ref9","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1001\/jama.296.19.2329","article-title":"Adjuvant radiotherapy for pathologically advanced prostate CancerA randomized clinical trial","volume":"296","author":"Thompson","year":"2006","journal-title":"JAMA"},{"key":"2026032605555587500_ref10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","article-title":"Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02\/AUO AP 09\/95 trial","volume":"66","author":"Wiegel","year":"2014","journal-title":"Eur Urol"},{"key":"2026032605555587500_ref11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41598-023-50434-4","article-title":"Impact of radiation doses on clinical relapse of biochemically recurrent prostate cancer after prostatectomy","volume":"14","author":"Takano","year":"2024","journal-title":"Sci Rep"},{"key":"2026032605555587500_ref12","doi-asserted-by":"publisher","first-page":"v129","DOI":"10.1093\/annonc\/mdq174","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Horwich","year":"2010","journal-title":"Ann Oncol"},{"key":"2026032605555587500_ref13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/JU.0000000000003892","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part I: Introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"2026032605555587500_ref14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/JU.0000000000003891","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part II: treatment delivery for non-metastatic biochemical recurrence after primary radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"2026032605555587500_ref15","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026032605555587500_ref16","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.annonc.2024.03.010","article-title":"Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)","volume":"35","author":"Parker","year":"2024","journal-title":"Ann Oncol"},{"key":"2026032605555587500_ref17","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026032605555587500_ref18","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.22.02489","article-title":"Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death","volume":"41","author":"Tilki","year":"2023","journal-title":"JCO"},{"key":"2026032605555587500_ref19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.prro.2019.04.008","article-title":"Adjuvant and salvage radiation therapy after prostatectomy: ASTRO\/AUA guideline amendment, executive summary 2018","volume":"9","author":"Pisansky","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"2026032605555587500_ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.781040","article-title":"Post-operative radiotherapy in prostate cancer: is it time for a belt and braces approach? Front","volume":"11","author":"Giraud","year":"2021","journal-title":"Oncologia"},{"key":"2026032605555587500_ref21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.clon.2013.06.012","article-title":"Understanding radiation-induced cardiovascular damage and strategies for intervention","volume":"25","author":"Stewart","year":"2013","journal-title":"Clin Oncol"},{"key":"2026032605555587500_ref22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"2026032605555587500_ref23","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.ijrobp.2020.11.009","article-title":"Hypofractionated Postprostatectomy radiation therapy for prostate cancer to reduce toxicity and improve patient convenience: a phase 1\/2 trial","volume":"109","author":"Wages","year":"2021","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"2026032605555587500_ref24","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"As","year":"2024","journal-title":"N Engl J Med"},{"key":"2026032605555587500_ref25","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1002\/cncr.25824","article-title":"Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence","volume":"117","author":"Kruser","year":"2011","journal-title":"Cancer"},{"key":"2026032605555587500_ref26","first-page":"2785","article-title":"Hypofractionated intensity-modulated radiotherapy with simultaneous integrated boost after radical prostatectomy: preliminary results of a phase II trial","volume":"33","author":"Massaccesi","year":"2013","journal-title":"Anticancer Res"},{"key":"2026032605555587500_ref27","first-page":"4537","article-title":"Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer","volume":"33","author":"Alongi","year":"2013","journal-title":"Anticancer Res"},{"key":"2026032605555587500_ref28","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.eururo.2014.06.012","article-title":"Higher-than-expected severe (grade 3\u20134) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients","volume":"66","author":"Cozzarini","year":"2014","journal-title":"Eur Urol"},{"key":"2026032605555587500_ref29","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ijrobp.2025.04.002","article-title":"Severe late toxicities (grade 3-5) with 13 years of follow-up after Hypofractionated Postprostatectomy radiotherapy","volume":"123","author":"Ranta","year":"2025","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"2026032605555587500_ref30","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1209978","article-title":"Long-term functional outcomes after treatment for localized prostate cancer","volume":"368","author":"Resnick","year":"2013","journal-title":"N Engl J Med"},{"key":"2026032605555587500_ref31","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ijrobp.2023.04.032","article-title":"Salvage radiation therapy after radical prostatectomy: analysis of toxicity by dose-fractionation in the RADICALS-RT trial","volume":"117","author":"Petersen","year":"2023","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"2026032605555587500_ref32","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.clon.2014.12.003","article-title":"Accelerated hypofractioned postoperative radiotherapy for prostate cancer: a prospective phase I\/II study","volume":"27","author":"Gladwish","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2026032605555587500_ref33","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ijrobp.2015.11.025","article-title":"Image guided Hypofractionated Postprostatectomy intensity modulated radiation therapy for prostate cancer","volume":"94","author":"Lewis","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026032605555587500_ref34","first-page":"5821","article-title":"Hypofractionated postoperative IMRT in prostate carcinoma: a phase I\/II study","volume":"37","author":"Macchia","year":"2017","journal-title":"Anticancer Res"},{"key":"2026032605555587500_ref35","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.ijrobp.2014.07.015","article-title":"Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial","volume":"90","author":"Katayama","year":"2014","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"2026032605555587500_ref36","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1001\/jamaoncol.2023.7291","article-title":"Noninferiority of Hypofractionated vs conventional Postprostatectomy radiotherapy for genitourinary and gastrointestinal symptoms: the NRG-GU003 phase 3 randomized clinical trial","volume":"10","author":"Buyyounouski","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026032605555587500_ref37","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1001\/jamaoncol.2025.1059","article-title":"Patient-reported outcomes with stereotactic intensity modulated radiotherapy after radical prostatectomy: a nonrandomized clinical trial","volume":"11","author":"Nikitas","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026032605555587500_ref38","volume-title":"POst-Prostatectomy Ablative Radiation Therapy","author":"Arcangeli"},{"key":"2026032605555587500_ref39","volume-title":"Multicenter Study of Hypofractionated Postoperative Radiotherapy in Patients Diagnosed with Prostate Carcinoma","author":"Hervas"},{"key":"2026032605555587500_ref40","volume-title":"Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients with Localized Prostate Cancer: A Treatment Feasibility and Outcomes Study","author":"Tseng"},{"key":"2026032605555587500_ref41","volume-title":"Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for Adjuvant or Salvage Treatment for Rising PSA after Radical Prostatectomy (EXCALIBUR)","author":"Jonsson Comprehensive Cancer Center"},{"key":"2026032605555587500_ref42","volume-title":"Early Salvage Stereotactic Radiotherapy (esSBRT) for Biochemical Failure after Radical Prostatectomy\u00a0:A Phase II Study","author":"Sanguineti"},{"key":"2026032605555587500_ref43","volume-title":"A Single Arm Phase II Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence after Radical Prostatectomy","author":"Insel Gruppe AG, University Hospital Bern"},{"key":"2026032605555587500_ref44","volume-title":"Salvage Stereotactic Body Radiotherapy of the Prostate Bed for Biochemical Recurrence after Radical Prostatectomy","author":"Jules Bordet Institute"},{"key":"2026032605555587500_ref45","volume-title":"Stereotactic Hypofractionated Accelerated Radiotherapy Post-Prostatectomy: A Phase I Feasibility Study","author":"Greco"},{"key":"2026032605555587500_ref46","volume-title":"Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients with Localized Prostate Cancer: A Treatment Feasibility and Outcomes Multicenter Study","author":"Tseng","year":"2025,   )"},{"key":"2026032605555587500_ref47","volume-title":"A Phase II Randomized Trial of Moderate Versus Ultra-Hypofractionated Post-Prostatectomy Radiation Therapy","author":"University of Michigan Rogel Cancer Center"},{"key":"2026032605555587500_ref48","volume-title":"Salvage Ultrahypofractionated Postoperative External Radiotherapy for Biochemical Recurrence","author":"University of Milano Bicocca"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/67\/2\/161\/67092612\/rrag006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/67\/2\/161\/67092612\/rrag006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:56:06Z","timestamp":1774518966000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/article\/67\/2\/161\/8496201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,24]]},"published-print":{"date-parts":[[2026,3,25]]}},"URL":"https:\/\/doi.org\/10.1093\/jrr\/rrag006","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"value":"0449-3060","type":"print"},{"value":"1349-9157","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,24]]}}}